Polarean, Inc.

Polarean, Inc. is a medical device company specializing in Xenon MRI imaging technology for pulmonary diagnostics. The company develops hyperpolarized xenon-129 MRI systems designed to provide direct measurement of regional lung function in a single 10–15 second breath-hold, addressing limitations of conventional lung imaging modalities. Polarean's product platform includes the HPX Hyperpolarizer (supplies high-purity hyperpolarized xenon gas), HPX Measurement Station (calibrated polarization measurement), HPX Gas Manifold (gas pressure regulation and purification), Xenon Xe-129 Gas Blend, and a specialized Chest Coil designed for xenon MRI scanning. The technology targets patients with chronic lung diseases including idiopathic pulmonary fibrosis (IPF), COPD, pulmonary hypertension, radiation therapy sequelae, cystic fibrosis, and asthma. Polarean holds FDA approval for its xenon MRI platform and conducts ongoing clinical research to establish safety and efficacy. The company markets to clinicians, hospital administrators, researchers, and industry collaborators globally. Manufacturing and service capabilities include hyperpolarizer systems, gas preparation, and measurement station calibration.